Press releases

Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) today announces that Nasdaq has informed the Company that it currently does not fulfil the ongoing listing requirement regarding active operations. In accordance with applicable rules, Nasdaq may therefore delist the Company’s financial instruments...

Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) hereby provides an update regarding the strategic review that was announced in December 2025.

Guard Therapeutics (publ) today announces changes to the company’s management team, in light of the conclusion of the clinical program for the drug candidate RMC-035 and the ongoing strategic review focused on a merger or a reverse takeover (RTO).

Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) hereby provides a status update regarding the strategic review that the Company announced through a press release on 4 December 2025. The review, which includes an exploration of potential strategic alternatives, including the identification of potential...

Guard Therapeutics (publ) today announced its participation as a partner in a newly funded European research consortium under the 2025 Joint Transnational Call from the European Rare Diseases Research Alliance (ERDERA), aimed at accelerating the development of therapies for rare kidney diseases.